Galderma, a global dermatology company, has received filing acceptances for its breakthrough treatment nemolizumab. The drug is designed to treat prurigo nodularis and moderate-to-severe atopic dermatitis in adolescents and adults. It received regulatory nods from authorities in Australia, Singapore, Switzerland, and the United Kingdom via the Access Consortium framework.
Log In or Register as a healthcare professional to read the full article.
